The Semmelweis University and Egis Pharmaceuticals PLC have agreed on an even closer and better structured cooperation than before. Their common goal is to further raise the standards of pharmaceutical R+D as well as pharmacist and doctor training by making use of the synergies in each other’s activities. As a result of the agreement, new health industrial innovations can be launched and the Semmelweis University can be extended with more practical educational and training elements that also meet the needs of the Hungarian pharmaceutical industry.

Egis and our consortia partners have won 2,332 billion HUF direct grant in the framework of the innovation tender GINOP-2.2.1-15-2016-00023 for the realization of the above-mentioned project.

Egis Pharmaceuticals PLC acquired Sinuforte from Hartington Business S.L. Under the agreement Egis receives all rights related to the product, a nasal spray indicated for the treatment of sinusitis and other inflammatory diseases of the paranasal sinuses. The company seeks to ensure its growing presence in major export markets through organic growth and targeted acquisitions.

Egis Pharmaceuticals PLC has acquired Sorbifer’s product rights from AstraZeneca. The transaction reinforces Egis’ position on its key markets.

In July 2025, 135 employees from across Russia took part in the first-ever corporate sports camp EgiSport — a 21-day online marathon created by employees, for employees. With no external contractors and full creative freedom, the project became more than just a fitness initiative — it turned into a true celebration of corporate culture and team spirit.

Egis Pharmaceuticals Plc. applied for the prestigious Top Employer Hungary certification for the first time and successfully joined the ranks of companies recognized for their outstanding employer practices on an international level.

The predecessor of Egis Pharmaceuticals PLC, Dr Wander Pharmaceuticals and Nutriments Ltd. was registered on 19 February 1913.

EGIS-RUS received the honor from Aon Hewitt, the global leader in human resource solutions and its Russian partner AXES Management

Over the past four years, our company has made significant progress in the field of oncological active ingredient and preparation development, thanks to the support received through the project titled ´Development of innovative, high added value oncological drug preparations for personalized therapies.´ During the period from 2021 to 2024, we worked on the development of 14 active ingredients and 5 preparations in collaboration with our consortium partner, HUN-REN TTK.

The Russian market of anticoagulants has been expanded with European rivaroxan produced by Egis Pharmaceuticals PLC (Hungary). The product from the class of direct oral anticoagulants combines European manufacturing standards and practical benefits for patients. With a convenient one-pill-per-day regime and affordability, this product opens up new possibilities in the prevention of thrombosis, significantly increasing the availability of modern anticoagulation therapy and contributing to improved patient commitment to long-term treatment.

Two of Egis’ fixed-dose combination drugs have won the Innovation Grand Prize. The awarded Egis medicines feature significant innovations as they reduce the risk of cardiovascular events related to atherosclerosis due to the combined lipid-lowering therapy. In respect of these two products the company obtained three patents related to active ingredient development and two patents related to formulation development that are all relevant to large-scale manufacturing technologies. The recognition was not without a history, as this is the tenth time an Egis medicine has received an Innovation Prize or Grand Prize.

Egis launches in Russia a product with fixed-doses of atorvastatin and ezetimibe in one capsule for the treatment of hypercholesterolemia [1]. Fixed-dose combination (FDC) developed by Egis will increase adherence in patients who take atorvastatin and ezetimibe separately, and a single dose per day should significantly simplify the drug therapy regimen.

Egis and Patient Community Join Forces at First Public Roundtable on Alzheimer’s Disease

On February 26, 2025, the Parents´ Choice Association of Consumers and Manufacturers of Children´s Products awarded the winners of the Parents´ Choice 2025 award! According to the results of the vote of the national jury in the nomination ˝Women´s Health˝, the Vagilak Proledi brand for women´s intimate health (Egis became the winner.

The 19th National Congress of Therapists with international participation was held on November 20-22, 2024 in Moscow, which became a key event for the Russian Scientific Medical Society of Therapists. The congress was organized by the Ministry of Health of the Russian Federation, the Russian Academy of Sciences, and the Russian Medical Scientific Society of Therapists. Egis, acting as one of the General Sponsors, organized three satellite symposia dedicated to healthcare issues: iron deficiency, anxiety disorders, cardiovascular diseases, and hyperuricemia.

EGIS-RUS LLC has completed the transition to a unified solution for dietary supplements and drug movement labeling and traceability system in the Utrace HUB management system.